Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN
October 21st 2024Erminia Massarelli, MD, PhD, MS, presents 5-year progression-free survival and safety data from the CROWN study comparing lorlatinib with crizotinib in treatment-naïve patients with advanced ALK+ NSCLC.
Current Landscape of Relapsed/ Refractory Multiple Myeloma
October 18th 2024Panelists discuss how the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM) includes standard options like such as IMiDs, PIs, and mAbs, while highlighting the emergence of novel therapies such as CAR T- cells and bispecific antibodies, which address unmet needs and offer potential advantages in treatment efficacy and patient outcomes.
Challenging Adverse Events with GPRC5D-Targeted Therapies
October 18th 2024Panelists discuss how cytokine release syndrome and neurological toxicities have been the most challenging adverse events to manage with GPRC5D-targeted therapies, requiring proactive monitoring and intervention strategies, while noting that these side effects are generally similar to those seen with other bispecifics.
Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy
October 18th 2024Panelists discuss how the CARTITUDE-4 study data provide a comprehensive overview of its design, baseline characteristics, and efficacy outcomes, highlighting the potential of ciltacabtagene autoleucel in improving treatment results for patients with lenalidomide-refractory multiple myeloma.
ctDNA in CRC Management: Evolving Approaches for Personalized Care
October 16th 2024Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.
Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
October 16th 2024Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.